Pacific Biosciences of California, Inc.
PACBHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframePacific Biosciences of California, Inc. operates in the Medical Devices space. Pacific Biosciences of California, Inc. With a market capitalization of $655.9M, it sits in small-cap territory. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Market Cap
$655.9M
Beta
2.19
P/E (TTM)
—
P/E (Fwd)
-5.01
EPS (TTM)
$-0.43
EPS (Fwd)
$-0.42
ROE
-929.3%
ROA
-14.1%
Cash
$236.9M
Total Debt
$709.1M
Free CF
$291.6M
52W Change
1.0%
Annual Financials
Cash vs Debt
Where PACB stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, PACB finished 31.54% above its 150-day moving average ($1.49) and 22.50% above its 200-day moving average ($1.60). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PACB overbought or oversold?
At the October 16, 2026 close, PACB's RSI(14) was 57.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Pacific Biosciences of California, Inc. carries $709.1M in total debt against $236.9M in cash reserves — debt is roughly 3.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $291.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -929.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $128.3M (2022) to $160.0M (2025), reflecting a 25% increase over the period.
A beta of 2.19 means PACB is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Pacific Biosciences of California, Inc. and its sector.